STOCK TITAN
  1. Home
  2. News
  3. WINT

Windtree Therapeutics, Inc. - WINT STOCK NEWS

Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.

Windtree Therapeutics, Inc. (NASDAQ: WINT) is a pioneering biotechnology company specializing in the development of innovative therapies for critical cardiovascular and respiratory conditions. The company's advanced research and proprietary technologies aim to address significant unmet medical needs, offering hope to patients and their families.

At the core of Windtree's portfolio is its KL4 surfactant technology, a synthetic, peptide-containing surfactant structurally similar to human pulmonary surfactant. This technology is being developed for noninvasive administration via aerosolization, with a primary focus on treating Respiratory Distress Syndrome (RDS) in premature infants. The potential of this technology extends to various other respiratory diseases, promising new therapeutic avenues where few or no approved treatments exist.

In the cardiovascular domain, Windtree is advancing istaroxime, a Phase 2 candidate exhibiting unique dual mechanisms that enhance both systolic and diastolic cardiac functions. Istaroxime targets acute heart failure and cardiogenic shock, conditions with high mortality and limited treatment options. Recent collaborations, including a significant license agreement with Lee's Pharmaceutical, aim to develop and commercialize istaroxime in Greater China, reflecting its global potential.

Windtree is also exploring preclinical SERCA2a activators for heart failure, aiming to develop both intravenous and oral formulations to treat acute and chronic heart failure, respectively. Additionally, the company is advancing rostafuroxin, targeting hypertension in patients with specific genetic markers, and a preclinical atypical protein kinase C iota (aPKCi) inhibitor, for potential oncology applications.

Financially, Windtree's strategic licensing and partnerships, such as the recent agreement with Deerfield Management to retire a $15 million liability, have strengthened its balance sheet. The company is strategically positioned to advance its late-stage clinical programs while optimizing its financial resources to support ongoing and future endeavors.

Windtree's commitment to scientific innovation and strategic collaborations is poised to transform treatment paradigms in cardiovascular and respiratory care, with a robust pipeline that holds significant promise for the future.

News

Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates

Rhea-AI Summary
Windtree Therapeutics, Inc. reported its financial results for Q4 and year-end 2023, highlighting key business updates. The company acquired a novel oncology preclinical aPKCi inhibitor platform, entered into partnerships for istaroxime development, and renewed collaborations. Financially, R&D expenses decreased, while operating losses and net losses improved compared to the previous year. Cash and cash equivalents stood at $4.3 million with current liabilities at $4.0 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
earnings
-
News

Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing

Rhea-AI Summary
Windtree Therapeutics, Inc. announced the acquisition of assets from Varian Biopharmaceuticals, Inc., including a novel protein kinase inhibitor with potential in oncology and rare malignant diseases. The Company completed a $1.5 million convertible note bridge financing to support this acquisition. The acquired asset platform includes two formulations: VAR-101 (topical) and VAR-102 (oral). Windtree issued 5,500 shares of Series B Convertible Preferred Stock to Varian's creditor investors. The Company plans to pay up to $2.3 million in milestone payments for regulatory and clinical development achievements. The acquired protein kinase inhibitor targets the PKC family, specifically aPKCi, showing promising pre-clinical data in various tumor types. Windtree aims to leverage this acquisition to enhance its product candidate portfolio and advance its development programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.76%
Tags
acquisition
-
News

Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research

Rhea-AI Summary
Windtree Therapeutics, Inc. renews partnership with Chang Gung University in Taiwan to further research on SERCA2a, an important target for the Company’s cardiovascular portfolio. The collaboration includes istaroxime and next-generation compounds called SERCA2a activators. Windtree believes SERCA2a activation could represent an important advancement in heart failure treatment. Istaroxime is being studied in the Phase 2 SEISMiC Extension Study in early cardiogenic shock. Market research revealed a high demand for new drug innovation to treat cardiogenic shock patients, with an estimated worldwide total market value of $1.25 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
none
News

Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives

Rhea-AI Summary
Windtree Therapeutics, Inc. has engaged Ladenburg Thalmann & Co. Inc. to evaluate strategic alternatives with the goal of maximizing stockholder value. The company has made significant progress in advancing its cardiovascular portfolio, including clinical trials in cardiogenic shock and a licensing deal with Lee’s Pharmaceuticals for the Greater China-Asia Pacific region. Windtree is actively exploring strategic alternatives such as acquisition, merger, further licensing, or company sale to maximize shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
none
-
News

Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company

Rhea-AI Summary
Windtree Therapeutics (NASDAQ:WINT) has announced a significant agreement with Deerfield Management Company to retire a $15 million liability associated with its Aerosurf drug and device combination treatment for premature infants. The company has strengthened its financial position and balance sheet, with no significant debt and increased shareholder equity. Windtree is also targeting Phase 3 readiness in cardiogenic shock with its lead asset istaroxime, which has shown promising results in a phase 2 study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
-
News

Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company

Rhea-AI Summary
Windtree Therapeutics, Inc. has entered into an Exchange and Termination Agreement with Deerfield Management Company to terminate its rights to receive up to $15,000,000 in development and commercial milestone payments associated with AEROSURF®. In exchange, Windtree will issue 608,272 shares of common stock and pay Deerfield $100,000 in cash. The company also agreed to pay an additional $100,000 upon meeting certain conditions. Windtree's President and CEO, Craig Fraser, expressed appreciation for Deerfield's support and stated that the company has strengthened its balance sheet, reduced cash burn rate, and made progress in clinical trials for its lead asset, istaroxime.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
none
News

Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China

Rhea-AI Summary
Windtree Therapeutics Inc. (NASDAQ:WINT) has entered into a license agreement with Lee's Pharmaceutical (HK) Ltd. to develop and commercialize its product candidate istaroxime for acute heart failure and cardiogenic shock in the greater China region. The deal supports Windtree's pipeline treatments for acute heart failure and cardiogenic shock and has the potential to provide financial support for development of treatment to address an unmet need and a growing problem in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region

Rhea-AI Summary
Windtree Therapeutics, Inc. has entered into a license agreement with Lee’s Pharmaceutical (HK) Limited for the development and commercialization of istaroxime in Greater China, including for acute heart failure and cardiogenic shock. The agreement also includes the licensing of Windtree’s next-generation SERCA2a activators and rostafuroxin. Lee’s will fund Phase 3 for istaroxime and will be responsible for all development, manufacturing, regulatory, and commercial costs for the covered products in the licensed region. Windtree is entitled to receive up to $138.1 million in payments upon the achievement of certain milestones plus up to low double-digit royalties. The agreement also establishes joint committees to oversee regional development and commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.64%
Tags
none
-
News

Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator

Rhea-AI Summary
Windtree Therapeutics, Inc. (WINT) announced new preclinical data on the Company’s lead product candidate, istaroxime, and another preclinical pipeline drug candidate, CVie-216, showing reductions in ventricular arrythmias in a rat heart model of diabetes with restricted and restored coronary blood flow induced injury.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.43%
Tags
none
News

Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024

Rhea-AI Summary
Windtree Therapeutics, Inc. (NASDAQ:WINT) has started phase 2 SEISMiC Extension Study for istaroxime in early cardiogenic shock treatment, aiming to build on positive SEISMiC study data and facilitate the end-of-phase 2 meeting with the FDA. Cardiogenic shock has a high mortality rate and unmet need for drug treatment. Market research shows the potential for istaroxime, with 84% of cardiologists willing to use it. Istaroxime has already shown positive results in treating cardiogenic shock, and the SEISMiC Extension Study is expected to pave the way for a phase 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
clinical trial

FAQ

What is the current stock price of Windtree Therapeutics (WINT)?

The current stock price of Windtree Therapeutics (WINT) is $0.3038 as of December 24, 2024.

What is the market cap of Windtree Therapeutics (WINT)?

The market cap of Windtree Therapeutics (WINT) is approximately 2.7M.

What is Windtree Therapeutics' primary focus?

Windtree Therapeutics focuses on developing innovative therapies for critical cardiovascular and respiratory conditions.

What is the KL4 surfactant technology?

KL4 surfactant technology is a synthetic, peptide-containing surfactant structurally similar to human pulmonary surfactant, aimed at treating respiratory diseases, including RDS in premature infants.

What is istaroxime?

Istaroxime is a Phase 2 candidate developed by Windtree Therapeutics to treat acute heart failure and cardiogenic shock by improving both systolic and diastolic cardiac functions.

What recent partnership has Windtree Therapeutics engaged in?

Windtree Therapeutics has entered a significant partnership with Lee's Pharmaceutical to develop and commercialize istaroxime in Greater China.

What is rostafuroxin?

Rostafuroxin is a drug candidate targeting hypertension in patients with specific genetic profiles, currently under development by Windtree Therapeutics.

How has Windtree Therapeutics strengthened its financial position?

Windtree has strengthened its financial position through strategic licensing agreements and partnerships, such as retiring a $15 million liability with Deerfield Management.

What are SERCA2a activators?

SERCA2a activators are compounds developed by Windtree that enhance cardiac function and are being explored for both intravenous and oral treatments for heart failure.

What is the potential market impact of istaroxime?

If approved, istaroxime could become a standard treatment for improving blood pressure and heart function in patients with acute heart failure and cardiogenic shock.

What is Windtree's approach to oncology?

Windtree is developing a preclinical atypical protein kinase C iota (aPKCi) inhibitor for potential applications in rare and broad oncology indications.

Where can I find more detailed financial information about Windtree Therapeutics?

Detailed financial information can be found in Windtree's Annual Report on Form 10-K and other filings available at www.sec.gov.

Stock WINT logo
Windtree Therapeutics, Inc.

Nasdaq:WINT

WINT Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

WINT Stock Data

2.73M
8.96M
0.27%
2.06%
0.35%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WARRINGTON